- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06654752
Tratamiento simplificado de las exacerbaciones pulmonares en pediatría (STOP PEDS RCT)
Tratamiento simplificado de las exacerbaciones pulmonares en un ensayo controlado aleatorio en pediatría (STOP PEDS RCT)
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.
Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.
The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.
Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:
- Clinic throat swab substudy
- Home throat and nasal swab substudy
- Remote monitoring substudy (Home monitoring of lung function, vital signs, activity and sleep)
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Erika Enright
- Número de teléfono: 206-897-1922
- Correo electrónico: eenright@uw.edu
Ubicaciones de estudio
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6H 3V4
- Reclutamiento
- British Columbia Children's Hospital
-
Investigador principal:
- Jonathan Rayment, MD
-
Contacto:
- Ronak S Ravandi
- Correo electrónico: ronak.salamatravandi@bcchr.ca
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 0A4
- Reclutamiento
- The Hospital for Sick Children & Toronto Canada CF Centre Pediatrics
-
Investigador principal:
- Felix Ratjen, MD
-
Contacto:
- Claire Crompton
- Correo electrónico: claire.crompton@sickkids.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Reclutamiento
- The Children's Hospital Alabama & University of Alabama at Birmingham
-
Investigador principal:
- Christopher Fowler, MD
-
Contacto:
- Valerie Tarn
- Número de teléfono: 2056385134
- Correo electrónico: vtarn@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85713
- Reclutamiento
- Tucson Cystic Fibrosis Center
-
Investigador principal:
- Cori Daines, MD
-
Contacto:
- Elizabeth (Lisa) Ryan
- Correo electrónico: elizabethryan@arizona.edu
-
-
California
-
Los Angeles, California, Estados Unidos, 90027
- Reclutamiento
- Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic
-
Investigador principal:
- Martha McKinney, MD
-
Contacto:
- Ariana Teame, BA
- Correo electrónico: ateame@chla.usc.edu
-
Palo Alto, California, Estados Unidos, 94304
- Reclutamiento
- Stanford University
-
Contacto:
- Tina Conti, BSRC, RRT, RRT-NPS, C-NPT
- Correo electrónico: tconti@stanford.edu
-
Investigador principal:
- Lori WaiHang Lee, MD
-
San Diego, California, Estados Unidos, 92123
- Aún no reclutando
- Rady Children's Hospital at University of California San Diego
-
Contacto:
- Lisa Ramos, CRC
- Correo electrónico: lramosvallejo@health.ucsd.edu
-
Investigador principal:
- Kathryn Akong, MD
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- Children's Hospital of Colorado
-
Investigador principal:
- Jordana Hoppe, MD
-
Contacto:
- Mary Cross
- Correo electrónico: Mary.Cross@childrenscolorado.org
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Children's Healthcare of Atlanta & Emory University
-
Contacto:
- Joy Dangerfield
- Correo electrónico: jdanger@emory.edu
-
Investigador principal:
- Ajay Kasi, MD
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University
-
Investigador principal:
- Maria Dowell, MD
-
Contacto:
- Lisa Gallo, CRC
- Número de teléfono: 312-227-2473
- Correo electrónico: lgallo@luriechildrens.org
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Reclutamiento
- Riley Hospital for Children & Indiana University
-
Contacto:
- Lisa Bendy
- Correo electrónico: lbendy@iu.edu
-
Investigador principal:
- D. B. Sanders, MD, MS
-
Contacto:
- Misty Thompson
- Correo electrónico: misthomp@iu.edu
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa
-
Contacto:
- Mary Teresi
- Correo electrónico: mary-teresi@uiowa.edu
-
Investigador principal:
- Anthony Fischer, MD
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Reclutamiento
- Johns Hopkins Hospital, Johns Hopkins University
-
Contacto:
- Jamelia Maynard
- Correo electrónico: jmaynar8@jhmi.edu
-
Investigador principal:
- Peter Mogayzel, MD, PhD, MBA
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Boston Children's Hospital & Harvard University
-
Contacto:
- Monica Ulles
- Correo electrónico: monica.ulles@childrens.harvard.edu
-
Investigador principal:
- Gregory Sawicki, MD
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109-5212
- Reclutamiento
- University of Michigan Health System
-
Contacto:
- Dawn Kruse
- Correo electrónico: dmkruse@med.umich.edu
-
Investigador principal:
- Samya Nasr, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55404
- Reclutamiento
- Children's Hospitals and Clinics of Minnesota
-
Investigador principal:
- Brooke Moore, MD
-
Contacto:
- Danniella Balangoy
- Correo electrónico: Danniella.Balangoy@childrensmn.org
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Reclutamiento
- The Minnesota Cystic Fibrosis Center & University of Minnesota
-
Investigador principal:
- Samuel Goldfarb, MD
-
Contacto:
- Alyssa Perry
- Correo electrónico: ahperry@umn.edu
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Reclutamiento
- Children's Mercy Hospital
-
Contacto:
- Jana Lomonte
- Correo electrónico: jblomonte@cmh.edu
-
Investigador principal:
- Hugo Escobar, MD
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- St. Louis Children's Hospital & Washington University School of Medicine
-
Investigador principal:
- Jessica Pittman, MD
-
Contacto:
- Taylor Haas, RN, BSN
- Correo electrónico: koenigt@wustl.edu
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- Reclutamiento
- University of Rochester Medical Center Strong Memorial
-
Contacto:
- Barbara Johnson, RN
- Correo electrónico: Barbara_johnson@urmc.rochester.edu
-
Investigador principal:
- Matthew McGraw, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Reclutamiento
- University of North Carolina at Chapel Hill
-
Investigador principal:
- Jennifer Goralski, MD
-
Contacto:
- Caroline Flowers, CRC
- Correo electrónico: caroline_flowers@med.unc.edu
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Reclutamiento
- Cincinnati Children's Hospital Medical Center
-
Investigador principal:
- Gary McPhail, MD
-
Contacto:
- Sharon Donnelly, RN, BSN, CPN
- Correo electrónico: sharon.kadon@cchmc.org
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239-3098
- Reclutamiento
- Oregon Health & Science University
-
Contacto:
- Pierce Nusbaum
- Correo electrónico: nusbaum@ohsu.edu
-
Investigador principal:
- Kelvin MacDonald, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Children's Hospital of Philadelphia & University of Pennsylvania
-
Investigador principal:
- Clement Ren, MD, MBA
-
Contacto:
- Matthew Gari
- Correo electrónico: garim@chop.edu
-
Contacto:
- Erin Donnelly
- Correo electrónico: donnellye4@chop.edu
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Reclutamiento
- Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center
-
Investigador principal:
- Daniel Weiner, MD
-
Contacto:
- Tyler Johnston, RN
- Correo electrónico: ateame@chla.usc.edu
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Reclutamiento
- Medical University of South Carolina
-
Investigador principal:
- Sylvia E Szentpeter, MD
-
Contacto:
- Anushka Phadke, CRC
- Número de teléfono: 843-792-4656
- Correo electrónico: phadke@musc.edu
-
Contacto:
- Sarah Shine, CRC
- Número de teléfono: 843-792-1221
- Correo electrónico: shinesa@musc.edu
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Reclutamiento
- University of Texas Southwestern & Children's Health
-
Investigador principal:
- Preeti Sharma, MD
-
Contacto:
- Lindsay Allen, CRC
- Correo electrónico: Lindsay.Allen@utsouthwestern.edu
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Texas Children's Hospital & Baylor College of Medicine
-
Investigador principal:
- Fadel Ruiz, MD
-
Contacto:
- Mayel Yepez
- Correo electrónico: Mayel.YepezDonado@bcm.edu
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05401
- Reclutamiento
- Vermont Children's Hospital & University of Vermont Medical Center
-
Investigador principal:
- Thomas Lahiri, MD
-
Contacto:
- Zachary Dichard
- Correo electrónico: Zachary.Dichard@uvmhealth.org
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23298
- Reclutamiento
- Virginia Commonwealth University
-
Contacto:
- Aleksander Subotic, CRC
- Correo electrónico: aleksandar.subotic@vcuhealth.org
-
Investigador principal:
- Michael T. Schechter, MD
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Reclutamiento
- Seattle Children's Hospital
-
Investigador principal:
- Margaret Rosenfeld, MD
-
Contacto:
- Marissa Nelson, CRC
- Número de teléfono: 206-987-3921
- Correo electrónico: marissa.nelsen@seattlechildrens.org
-
Contacto:
- Elizabeth Gore, RN, MPH
- Número de teléfono: 206-987-3317
- Correo electrónico: Liz.Gore@seattlechildrens.org
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Reclutamiento
- University of Wisconsin
-
Investigador principal:
- Hara Levy, MD
-
Contacto:
- Nikki Cole, BS, RRT, CCRC
- Correo electrónico: ndondlinger@wisc.edu
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- Children's Wisconsin & Medical College of Wisconsin
-
Investigador principal:
- Nicholas Antos, MD
-
Contacto:
- Laura Robertson, CCRC
- Correo electrónico: lrobertson@mcw.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Age
- For main cohort and non-HEMT cohort: age 6 to <19 years
- For preschool cohort: age 3 to <6 years
-
Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- sweat chloride ≥ 60 mEq/liter
- two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
-
Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study
-
Highly Effective Modulator Therapy
- For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment
- For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
-
For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry
-
For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations
-
Ability to receive text messages and access the internet
Exclusion Criteria:
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
- Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
- Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
- History of solid organ transplant
- History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
- Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
- Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
- Treatment with chronic oral antibiotics other than azithromycin at enrollment
- Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Immediate Antibiotics
Increased airway clearance plus early initiation of oral antibiotics |
Increase airway clearance and start 14 days of preselected oral antibiotics right away |
|
Experimental: Tailored Therapy
Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve |
Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
One-year change in pulmonary function by spirometry-measured ppFEV1
Periodo de tiempo: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease. |
1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
One-Year change in pulmonary function by LCI
Periodo de tiempo: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity [FRC]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level. |
1 year
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recovery to baseline by ppFEV1 and CRISS following a PEx
Periodo de tiempo: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Recovery to baseline by Lung Clearance Index (LCI)
Periodo de tiempo: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Safety Endpoint 1: Cumulative oral antibiotic exposure
Periodo de tiempo: 1 year
|
Compare cumulative oral antibiotic exposure in each treatment arm. |
1 year
|
|
Safety Endpoint 2: Number of respiratory illnesses
Periodo de tiempo: 1 year
|
Compare the number of respiratory illnesses reported over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx
Periodo de tiempo: 28 days
|
Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm. |
28 days
|
|
Safety Endpoint 4: Number of PEx treated with IV antibiotics
Periodo de tiempo: 1 year
|
Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28
Periodo de tiempo: 28 days
|
Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm. |
28 days
|
|
Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28
Periodo de tiempo: 1 year
|
Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm. |
1 year
|
|
Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness
Periodo de tiempo: 1 year
|
Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm. |
1 year
|
|
Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)
Periodo de tiempo: 1 year
|
Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm. |
1 year
|
|
Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures
Periodo de tiempo: 1 year
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm. |
1 year
|
|
Qualitative Assessment 1: Caregivers' experience managing study treatment
Periodo de tiempo: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Qualitative Assessment 2: Study treatment impact on child and family daily life
Periodo de tiempo: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Health care costs 1: Total estimated cost of antibiotics
Periodo de tiempo: 1 year
|
Compare total estimated cost of antibiotics used over the course of the study between treatment arms. |
1 year
|
|
Health care costs 2: Health care utilization
Periodo de tiempo: 1 year
|
Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits. |
1 year
|
|
Health care costs 3: Parent work productivity measures (WPAI)
Periodo de tiempo: 1 year
|
To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment. |
1 year
|
|
Preschool and non-HEMT Pilot Cohort Primary Feasibility
Periodo de tiempo: 28 days
|
Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx). |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery
Periodo de tiempo: 28 days
|
Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery
Periodo de tiempo: 28 days
|
Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events
Periodo de tiempo: 28 days
|
Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms
Periodo de tiempo: 28 days
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics
Periodo de tiempo: 28 days
|
Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx
Periodo de tiempo: 28 days
|
Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1
Periodo de tiempo: 28 days
|
Measure the proportion of approached patients that enrolls. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2
Periodo de tiempo: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3
Periodo de tiempo: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4
Periodo de tiempo: 28 days
|
Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm. |
28 days
|
|
Clinic Throat Swab Substudy 1: Metagenomic Sequencing
Periodo de tiempo: 1 year
|
Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms. |
1 year
|
|
Clinic Throat Swab Substudy 2: Microbiota Measures
Periodo de tiempo: 1 year
|
Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments. |
1 year
|
|
Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency
Periodo de tiempo: 28 days
|
Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis. |
28 days
|
|
Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing
Periodo de tiempo: 28 days
|
Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx). |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery
Periodo de tiempo: 28 days
|
Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1
Periodo de tiempo: 28 days
|
Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.
Periodo de tiempo: 28 days
|
Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment. |
28 days
|
|
Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes
Periodo de tiempo: 28 days
|
Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy. |
28 days
|
|
Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx
Periodo de tiempo: 28 days
|
Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study. |
28 days
|
|
Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx
Periodo de tiempo: 14 days
|
Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study. |
14 days
|
|
Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry
Periodo de tiempo: 28 days
|
Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28). |
28 days
|
|
Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures
Periodo de tiempo: 28 days
|
Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state. |
28 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx
Periodo de tiempo: 14 days
|
Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx
Periodo de tiempo: 14 days
|
Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx
Periodo de tiempo: 14 days
|
Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx
Periodo de tiempo: 14 days
|
Describe changes in sleep time from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages
Periodo de tiempo: 14 days
|
Compare changes in resting HR to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages
Periodo de tiempo: 14 days
|
Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages
Periodo de tiempo: 14 days
|
Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages
Periodo de tiempo: 14 days
|
Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)
Periodo de tiempo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate
Periodo de tiempo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level
Periodo de tiempo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration
Periodo de tiempo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Margaret Rosenfeld, MD, MPH, Seattle Children's Hospital
- Investigador principal: D. B. Sanders, MD, MS, Indiana University
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STOP PEDS RCT
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .